MARKET

IMRN

IMRN

Immuron Ltd
NASDAQ
2.070
-0.106
-4.87%
Closed 16:00 09/30 EDT
OPEN
2.100
PREV CLOSE
2.176
HIGH
2.100
LOW
2.000
VOLUME
9.92K
TURNOVER
13.32K
52 WEEK HIGH
4.478
52 WEEK LOW
2.000
MARKET CAP
11.79M
P/E (TTM)
-6.0594
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 08/31 12:07
Immuron CEO, Steven Lydeamore, to host an investor webinar
MELBOURNE, Australia, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; invite...
GlobeNewswire · 08/29 11:00
Immuron Pulls Plug On COVID-19 Treatment Hopeful, Citing Changing Landscape
Benzinga · 08/19 11:23
Immuron suspends research on COVID-19 program
Immuron (NASDAQ:IMRN) <a href="https://seekingalpha.com/pr/189109...
Seekingalpha · 08/19 10:33
Immuron Said Deprioritizing SARS-CoV-2 Research to Focus on Clinical Development of More Advanced Stage Therapeutic Drug Candidates
Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; today announced that it has deprioritized SARS-CoV-2 research to focus on the clinical development of our more advanced stage therapeutic drug candidates.
Benzinga · 08/19 10:02
Immuron Update on IMM-124E SARS-CoV-2 Research
MELBOURNE, Australia, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform for prevention and treatment of gut-mediated diseases; today ...
GlobeNewswire · 08/19 10:00
Immuron's IND Application For Bacterial Infection Candidate Placed On Clinical Hold
Benzinga · 07/26 11:07
Immuron says proposed trials of antibacterial drug put on clinical hold by FDA
The U.S. Food and Drug Administration placed<...
Seekingalpha · 07/26 11:05
More
About IMRN
Immuron Limited is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of polyclonal antibodies that can address unmet medical needs. The Company operates through two segments: Research and development (R&D) and Hyperimmune product. R&D segment focuses on R&D projects performed in Australia, Israel, and United States. Hyperimmune product segment is engaged in Travelan and Protectyn activities, which occurs in Australia, the Unites States and Canada. Its flagship products include Travelan and Protectyn. Travelan is a licensed natural health product and is indicated to reduce the risk of Travellers’ Diarrhea. Travelan is an over the counter immune supplement that can be taken to reduce the risk of diarrhea and reduce the symptoms of minor gastrointestinal disorders. Protectyn product helps to promote digestion and healthy gastrointestinal system health; support and maintain healthy liver function, and enhance immune defenses.

Webull offers kinds of Immuron Ltd stock information, including NASDAQ:IMRN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMRN stock methods without spending real money on the virtual paper trading platform.